Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Eculizumab (Soliris) for prevention of delayed graft function after kidney transplantation in adult patients at increased risk – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Eculizumab is a drug to prevent delayed graft function in people who have undergone a kidney transplant and are at a high risk of this complication. Delayed graft function means the transplant is not working effectively enough and that dialysis is needed within a week of transplantation. Eculizumab is delivered straight into the blood and prevents an immune response which may be the cause of delayed graft function. Indexing Status Subject indexing assigned by CRD MeSH Adult; Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Humans; Kidney Transplantation; Risk Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016001036 Date abstract record published 11/10/2016 |